Proteomic differentiation of leukemia cells based on multiplexed arrays and mass

基于多重阵列和质量的白血病细胞的蛋白质组分化

基本信息

批准号：
8451922
负责人：
W. Andy Tao
金额：
$ 30万
依托单位：
TYMORA ANALYTICAL OPERATIONS, LLC
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-09-16 至 2015-09-15
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8451922
关键词：
Acute Lymphocytic Leukemia Address Affinity Antibodies Antibody Specificity Behavior Biological Assay Biological Markers Biomedical Research Cell Line Cells Classification Clinical Data Set Detection Development Diagnosis Diagnostic tests Disease Disease Management Disseminated Malignant Neoplasm Flow Cytometry Gene Mutation Genes Global Change Goals Hematologic Neoplasms Human Hybrids Immunohistochemistry Immunophenotyping Individual Ions Lead Malignant Neoplasms Mass Spectrum Analysis Measurement Measures Molecular Monitor Mutation Oncogenic Pathway interactions Peptides Pharmaceutical Preparations Phase Phospho-Specific Antibodies Phosphopeptides Phosphorylation Phosphorylation Site Phosphotransferases Post-Translational Protein Processing Process Property Proteins Proteomics Reagent Reporting Research Personnel Resolution Sampling Signal Pathway Small Business Technology Transfer Research Specificity Staging Techniques Technology Testing United States National Institutes of Health Water anticancer research base cancer cell cancer diagnosis cancer type combat cost data acquisition disorder subtype fluorophore innovation innovative technologies inorganic phosphate leukemia nanopolymer neoplastic cell novel phase 1 study phase 2 study prototype public health relevance research and development research study response success therapeutic target tool

项目摘要

DESCRIPTION (provided by applicant): Although some gene mutations can predict response to certain targeted therapies, single-gene testing has limits. Multiple important signaling pathways that may be the causes of human malignancy have continuously been discovered and dissected. Pathway and network diagnostic tests are challenging but are clearly on the way. Through this NIH STTR Phase I study, we will develop a hybrid phosphoproteomic platform to differentiate leukemia at the molecular level. The platform features two innovative products recently introduced by us which are based on multi-functionalized water-soluble nanopolymers, allowing for highly selective, sensitive and simple qualitative and quantitative assessment of protein phosphorylation without the use of expensive phosphospecific antibodies. Due to its size and unique properties, it also offers the capability for multiplexed detection of phosphorylation and total protein amount simultaneously. Combined with targeted mass spectrometric analysis, this hybrid platform will be a powerful tool for biomedical research and development, particularly in the field of leukemia treatment, and a potential clinical tool for cancer diagnosis.

描述（由申请人提供）：尽管某些基因突变可以预测对某些靶向疗法的反应，但单基因测试仍有限制。可能是人类恶性肿瘤原因的多种重要信号通路已被连续发现和解剖。途径和网络诊断测试具有挑战性，但显然在路上。通过这项NIH STTR I期研究，我们将开发一个杂化磷蛋白平台，以区分分子水平的白血病。该平台采用了我们最近引入的两种创新产品，这些产品基于多功能水溶性纳米聚合物，可以对蛋白质磷酸化的高度选择性，灵敏和简单的定性评估，而无需使用昂贵的磷酸体特异性抗体。由于其大小和独特的特性，它还具有同时多路复用磷酸化和总蛋白质量的多路复用性检测能力。结合有针对性的质谱分析，该混合动力平台将成为生物医学研究和发育的强大工具，尤其是在白血病治疗领域，也是癌症诊断的潜在临床工具。